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Refsum’s Disease is an inherited metabolic disorder in which a metabolite of branched chain fatty acids accumulates due to lack
of appropriate oxidative enzymes. Patients have elevated plasma phytanic acid levels and high concentrations of phytanic acid
in a variety of tissues leading to progressive tissue damage. Besides retinal degeneration or retinal dystrophy associated with
adult onset retinitis pigmentosa, additional symptoms include chronic polyneuropathy, cerebellar ataxia, sensorineural hearing
loss, anosmia, ichthyosis, as well as skeletal, cardiac, hepatic, and renal abnormalities. Current management includes avoidance
of dietary sources of branched chain fatty acids and regular plasmapheresis to prevent accumulation of these compounds to
ameliorate progressive neurological deﬁcits. Two brothers with Refsum’s disease who experienced progressive symptoms despite
optimaldietandplasmapheresiswerecommencedonanoveltherapy.Wereporttheeﬀectoftheintestinallipaseinhibitor,Orlistat,
which led to signiﬁcant reduction (P-value < 0.001 on 2-sample unpaired t-test) of mean preplasmapheresis phytanic acid levels
with retardation of the progression of most of their dermatological and neurological symptoms.
1.Introduction
Refsum’s Disease, also known as heredopathia atactica
polyneuritiformis (HAP), was described by Norwegian neu-
rologist Sigvald Refsum in 1946. It is a rare complex disorder
that aﬀects many organs. It has an autosomal recessive
pattern of inheritance due to mutations on chromosome
10p13. Carriers are unaﬀected, however they may asymp-
tomatically exhibit slightly elevated phytanic acid levels,
whereas Refsum’s disease patients have markedly elevated
levels (normal <0.70mg/dL) [1].
Phytanic acid is a branched-chain fatty acid (BCFA),
formed by bacterial degradation of chlorophyll in the
intestinal tract of ruminants, invertebrates and, pelagic
ﬁsh [2]. Individuals with Refsum’s disease are unable to
metabolize phytanic acid by the β-oxidation pathway due to
deﬁciency of the peroxisome enzyme phytanoyl-CoA
hydroxylase (PAHX) [2–5] (Figure 1). It is essential for
the 3-methyl group in the β-position of this BCFA to be
removed by an α-oxidation step, activated by PAHX (within
the endoplasmic reticulum) in order to proceed with the
β-oxidation pathway. Peroxisomal β-oxidation is the most
eﬃcient mechanism for the metabolism of phytanic acid.
As a result, high levels of phytanic acid accumulate in
blood and other tissues, especially adipose tissue, neural
tissue, and astrocytes, where they cause oxidative stress
in mitochondria and oxidative damage during chronic
exposure [3, 6, 7] .I nas u b s e to fp a t i e n t s ,am u t a t i o n
of a second gene encoding for PEX7- peroxin 7 receptor
protein,involvedinperoxisomalimportofproteins,hasbeen
identiﬁed as a cause for the phenotype of Refsum’s disease
[2, 5].2 Journal of Obesity
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Figure 1: Metabolic pathway of phytanic acid. Phytanic acid is derived from microbial degredation of the phytol side chain of chlorophylls
ingested by ruminants, invertebrates, or pelagic ﬁsh. In humans the source is phytol from diet chlorophyll, or from meat, pelagic ﬁsh, or
diary. When digested it is in-cooperated into chylomicrons/VLDL and then transported to liver and tissues for further metabolism. Most
fatty acids are metabolised by β-oxidation pathways in peroxisomes and mitochondria.  denotes the enzyme deﬁcient in patients with
Refsum disease. # denotes the alternate less eﬃcient ω-oxidation pathway.
Early diagnosis of HAP or Refsum’s disease is important
because treatment is available to minimize progression.
Classical Refsum’s disease is usually diagnosed during child-
hood or early adulthood when visual problems due to
retinitis pigmentosa become apparent [1, 8]. Accumulation
of phytanic acid beneath the retina results in progressive
visual impairment. The presenting symptom is usually night
blindness followed by gradual loss of peripheral vision.
Cataracts, which are common in patients with retinitis
pigmentosa, may develop. Refsum’s disease leads to other
sensory complications, including impaired sense of smell,
usually occurring in early childhood but some times undi-
agnosed until other symptoms become apparent. Gradual or
sudden hearing loss can occur in adulthood, usually after the
3rd decade. Cardiac abnormalities include cardiomyopathy
or even fatal arrhythmias. Other neurological manifestations
include peripheral neuropathy, paraesthesia, and cerebella
ataxia. Ichthyosis, malaise, anorexia, and skeletal bone
abnormalities such as bony prominences around elbows,
knees and ankles and short digits of tubular bones of hands
or feet (especially the metatarsal of the fourth toe) are also
common. Renal and hepatic manifestations include tubularJournal of Obesity 3
Figure 2: Shortening of AF’s fourth toe, characteristic of Refsum’s
Disease.
dysfunction, aminoaciduria, and fatty degeneration [1, 5, 8–
11].
Humans have a secondary, less eﬃcient pathway for
phytanic acid metabolism via ω-oxidation, which is not
aﬀected in these patients [2, 5] (Figure 1). However the
capacity of ω-oxidation is limited and it is only suﬃcient to
process the reduced supply of phytanic acid associated with
dietaryrestriction.Itisreportedinanimalstudiesthatﬁbrate
drugs may induce this ω-oxidation pathway of phytanic acid
metabolism [2].
1.1. Current Management. Patients with Refsum’s disease
require multidisciplinary monitoring to detect cardiac, oph-
thalmic, and neurological manifestations. Humans do not
synthesizephytanicacid,obtainingitalmostexclusivelyfrom
their diet. Phytanic acid is found in meat, pelagic ﬁsh, and
dairy products [2]. Humans also convert phytol, a side chain
of chlorophyll found in green leafy vegetables, to phytanic
acid. It is impossible to achieve a diet that is completely free
of phytanic acid. Management of Refsum’s disease requires a
diet restriction of intake of phytanic acid to <10–20mg/day
(i.e., about 10% of that in a normal western diet) [1]. These
low phytanic acid (<10mg/dL) diets are very stringent [1].
Lowering of plasma phytanic acid levels by the long-term
adherence to diets low in phytanic acid and phytol may be
enhanced by serial plasma exchange to prevent development
or progression of neuropathy, ataxia, cardiac arrhythmias,
andichthyosis[1,10].Itislesscertainwhetherprogressionof
retinitis pigmentosa, anosmia or deafness can be prevented.
It is important that patients maintain body weight, since
rapid weight loss releases phytanic acid stored in body
tissues and increases symptoms. Similarly fevers, pregnancy,
and catecholamine released during plasmapheresis have
been associated with acute or subacute presentations that
mimic Guillain-Barre Syndrome or chronic inﬂammatory
demyelinating polyneuropathy.
1.2. Rationale for Treatment with Orlistat. Orlistat (Xenical)
is an inhibitor of intestinal lipase that blocks the digestion
of triglycerides. We hypothesised that it would therefore
reduce absorption of dietary branched chain fatty acids,
in particular phytanic acid. Orlistat is usually prescribed
for weight loss and has a favourable safety proﬁle which
has contributed to the decision to make it available across
the counter. Side eﬀects associated with Orlistat therapy
include diarrhoea, faecal incontinence following excessive fat
ingestion, and a slight decrease in absorption of fat soluble
vitamins. It must be noted that Orlistat-induced weight
loss might release adipose stores of phytanic acid, thereby
increasing plasma levels. We guarded against this possibility
by advising our patients to increase their calorie intake so as
to maintain weight.
2. Methods andPatients
The family comprised ﬁve children, four brothers and one
sister, born of consanguineous parents. There is no clear
history of a similar disorder in other generations of the
family. Brothers AF (50 years) and VF (48 years) were
diagnosed following the detection of the disorder in their
older brother ALF (56 years) who was living overseas. The
diagnosis of Refsum’s disease was made when ALF presented
to an ophthalmologist with progressive visual symptoms due
to retinitis pigmentosa. The family was screened, and the
younger brothers AF and VF were found to have elevated
plasma phytanic acid levels (AF 18.5–36mg/dL and VF
33–41mg/dL). In retrospect, brothers AF and VF reported
long standing symptoms of poor sense of smell, tinnitus,
loss of peripheral vision, and clumsiness. Examination
revealed anosmia, retinitis pigmentosa, constricted visual
ﬁelds,nystagmus,impairedcoordination,andataxiaonheel-
toe walking. AF also had an episode of nonsustained cardiac
arrhythmia, long-standing irritable bowel syndrome, and a
characteristic deformity in his fourth toes (Figure 2)w h i c h
was reported to be a feature in brother ALF as well. The
additional features in younger brother VF included hearing
impairment, ichthyosis, long slender toes, and multiple bony
prominences which are associated with Refsum’s disease.
Following conﬁrmation of the diagnosis by serum phy-
tanic acid measurements, both brothers commenced a low
phytanic diet and plasmapheresis. The plasma phytanic acid
levels at base-line and with dietary treatment plus plasma-
pheresis are shown in Figure 3(a). Despite this intensive
treatment, the two brothers continued to have progressive
symptoms and incomplete control of plasma phytanic acid
levels (greater than 10 times the upper limit of normal).
Substantially lower treatment goals were recommended to
minimize complications or progression of disease.
At this stage they were referred to the lipid and metabolic
disorder clinic at Royal Prince Alfred Hospital in Sydney for
further optimisation of treatment.
2.1. Method. AF and VF commenced treatment with Orlistat
at the standard dose of 120mg three times a day before
meals. However their compliance was incomplete and they
managed only two doses per day over the ﬁrst few months.
They continued a suitable low-phytanic acid diet with
adequate calorie intake to avoid weight loss and regular4 Journal of Obesity
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Figure 3: (a) Pre-plasmapheresis plasma phytanate (phytanic acid) levels. AF’s and VF’s preplasmapheresis phytanic acid levels before
and after addition of Orlistat (Xenical) therapy to diet and regular plasmapheresis (shown by arrow in June 2005) showing good control
of phytanic acid levels except during periods of non compliance with Orlistat therapy (in 2008) and weight loss (in 2007 and 2009). (b)
AF’s and VF’s mean plasma phytanic acid levels (mg/dL) before and after addition of Orlistat therapy to regular plasmapheresis and stable
low phytanic acid diet. AF’s and VF’s mean phytanic acid level before addition of Orlistat was 14.8mg/dL (SD 9.9) and 19.0mg/dL (SD
13.2), respectively. AF’s and VF’s mean phytanic acid level after addition of Orlistat therapy was 6.7mg/dL(SD 2.8) and 8.2mg/dL (SD5.5),
respectively, with a P-value <0.05 on two-sample t-Test.
(every 3 weeks) plasma exchanges. The mean pre plasma-
pheresis phytanic acid levels were calculated for the periods
before (April 2000–June 2005) and during (June 2005–
January 2010) Orlistat therapy, (Figure 3(b)). Nutritional
biochemical markers including fat soluble vitamin levels
were monitored at baseline and at regular intervals but
supplements were not required. Phytanic acid was measured
by gas chromatography using a 25m×0.32mm i.d. SGE BP-
20 capillary column; nonadecanoic acid (19:0) methylester
was used as internal standard and calibrated against phytanic
acid methyl ester (Ultra Scientiﬁc, USA).
3. Results
In AF, mean plasma phytanic acid level (Figure 3(b))o n
diet and plasmapheresis every 3 weeks was 14.8mg/dL (SD
10mg/dL), falling to 6.7mg/dL (SD 2.8mg/dL) after the
addition of unblinded orlistat therapy (P<0.05 on two-
sample t-Test). He reported clinical improvement in symp-
toms of polyneuropathy, ataxia, ichthyosis, irritable bowel
syndrome, and cardiac arrhythmia. In VF, mean plasma
phytanic acid level (Figure 3(b)) on diet and plasmapheresis
was 19.0mg/dL (SD 13.0mg/dL), falling to 8.2mg/dL (SD
5.5mg/dL) during unblinded orlistat therapy (P<0.05, two-
sample t-Test). This was associated with improvement in
symptoms of ataxia, hearing loss, and pruritus. However VF
continued to suﬀer progressive impairment of vision, which
has improved following bilateral cataract surgery. During
this period AF and VF maintained stable weight most of
the time with brief periods of weight loss associated with
a slight increase in measured phytanic acid levels resolving
with weight stabilisation, (Figure 3(a)).
4. Discussion
Early diagnosis of HAP or Refsum’s disease is important
because early treatment will minimize accumulation of
phytanic acid and progression of functional impairment
[1, 2]. Speciﬁc treatment for Refsum’s disease is limited. We
considered the use of Orlistat (Xenical), an intestinal lipase
inhibitor, hypothesising that it has the potential to reduce
the bioavailability of dietary phytanic acid. This occurs
because the inhibition of intestinal lipase by Orlistat results
in intestinal fat accumulation. Lipid soluble materials such
as phytanic acid are likely to partition into the triglyceride
phase and remain there until excreted. Indeed, signiﬁcant
reductions in mean pre-plasmapheresis plasma phytanic
acid levels were demonstrated, (Figure 3(b)) in these two
patients, without signiﬁcant adverse eﬀects or sustained
weight loss. Liberalisation of the restrictive diet or reduction
in the frequency of plasmapheresis may be feasible in
the setting of continued Orlistat therapy. Orlistat reduces
dietary triglyceride absorption by approximately 30%. In
future, it may be possible to intensify reduction in intestinal
lipolysis by the additional inhibition of lingual lipase. This
oﬀers the prospect of greater reductions in phytanic acid
absorption, but this must be balanced against the possibility
that associated weight loss might release tissue stores. It has
provided the most eﬀective means of reducing phytanic acid
levels and disease progression.
Orlistat might be useful in the treatment of other
metabolic disorders in which lipid soluble materials from the
intestine contribute to pathology. More speciﬁc treatment
for sitosterolaemia is available via the NPC1-L1 inhibitor,
ezetimibe. We have used Orlistat to treat chylomicronaemia
associated with massive hypertriglyceridaemia, which posesJournal of Obesity 5
a risk of acute pancreatitis. These patients remained free of
pancreatitis during Orlistat therapy, but triglyceride levels
and the clinical course of this condition are notoriously
variable. A large-scale randomised clinical trial of the use
of Orlistat would be required to assess its potential for
the prevention of pancreatitis in chylomicronaemia. This
report of the therapeutic eﬀect of Orlistat in Refsum’s
disease requires conﬁrmation in other patients. The use of
Orlistat to reduce plasma phytanic acid levels may permit a
reductionintheintensityofdiettherapyandplasmapheresis,
which would result in signiﬁcant beneﬁt to the patient
and reduction in the cost burden to health systems. It
may also favourably modify the progression of the clinical
manifestations of Refsum’s disease.
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